The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C Meds Impact Liver Transplant Outlook

Back to News Homepage

Next

FDA Approves 1st Treatment of 8 Weeks Duration for All HCV Genotypes

New FDA-Approved Triple-Drug-Regimen for Re-Treatment of Hep C

July 20, 2017

Print this page

Learn more about Gilead’s Vosevi for the re-treatment of Hepatitis C.

FDA Approves Gilead’s Vosevi for Re-treatment of Hepatitis C

The Food and Drug Administration (FDA) has approved 12 weeks of Gilead Sciences’ Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for the re-treatment of adults with all genotypes of hepatitis C virus (HCV) who do not have cirrhosis or who have compensated cirrhosis (the milder form of the severe liver disease).

More specifically, the approval is for a second hep C treatment for those with genotypes 1, 2, 3, 4, 5 or 6 who were previously treated with an HCV regimen containing a direct-acting antiviral (DAA) from the NS5A inhibitor class or for those with genotype 1a or 3 who were previously treated with a Sovaldi (sofosbuvir)-containing regimen that did not include an NS5A inhibitor.

Continue reading this entire article:
https://www.hepmag.com/article/fda-approves-gileads-vosevi-retreatment-hepatitis-c

For more information about Vosevi visit http://www.hepatitiscentral.com/vosevi-sofosbuvir-velpatasvir-and-voxilaprevir/what-is-vosevi/.

9 Comments
Share
Share

Previous

Hepatitis C Meds Impact Liver Transplant Outlook

Back to News Homepage

Next

FDA Approves 1st Treatment of 8 Weeks Duration for All HCV Genotypes

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.